DAVID ROSENSTEIN: Open Payments
NPI 1518001551 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 49 payments from 16 companies in 2025. Trend: 2023 $1,095 · 2024 $1,165 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $193 |
| PFIZER INC. | 9 | $181 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $99 |
| ABBVIE INC. | 4 | $82 |
| Astellas Pharma US Inc | 4 | $81 |
| Novo Nordisk Inc | 4 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| Medtronic, Inc. | 1 | $33 |
| Dexcom, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
Products named: TRELEGY ELLIPTA, NURTEC ODT, JARDIANCE, UBRELVY, Veozah, CAPLYTA, SHINGRIX, REXULTI.
Industry payments across NV — which companies pay providers there.
